Trial Profile
A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SECOMBIT
- 24 Oct 2023 Results assessing Brain metastases and survival evaluation presented at the 48th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 01 Sep 2022 Results published in the Journal of Clinical Oncology